Medivir AB

Great to hear when investigators in the study provide additional context to how the data we are generating in scientific experiments has the potential to positively impact the lives of patients. Our CMO Pia Baumann speaking with one of the most active investigators in the fostrox + Lenvima study about the new results presented at ESMO GI.

Our CMO Dr. Pia Baumann discusses the fostrox + Lenvima data recently presented at ESMO GI with Dr. Hong Jae Chon, CHA Bundang Hospital in Korea. Dr Chon has been one of the most active investigators in the study. At the time of recruiting patients, he was also involved in a couple of other 2L studies in HCC with a different treatment approach. In the discussion with Pia, he shares his experience across the studies and what role he could see for the fostrox + Lenvima combination, in light of the data update and the significant unmet medical need in 2L HCC.

One more interview for our CEO Jens Lindberg, this time by Klas Palin at Penser Access by Carnegie, about the improved results presented today at ESMO GI. Link to video in comments below.

Our CEO Jens Lindberg interviewed by Redeye about the new results presented today at ESMO GI. See link in comment section below.

Busy day ahead at ESMO GI for the team.

We will be presenting new data at the ESMO Gastrointestinal Cancers Congress 2024 in Munich!   Dr Hong Jae Chon is presenting a poster today detailing results from our Phase 1b / 2a open label trial of #fostrox + Lenvima®.   The data show #fostrox + Lenvima® has great promise as a second-line treatment for hepatocellular #carcinoma (#HCC), the most common type of #livercancer. These results come despite very poor prognosis for most second-line HCC patients today, with just 5 – 10% responding to current standard of care treatment.   If you are attending ESMO GI and would like to find out more, please get in touch and visit our poster number 176P. You can read the full press release using the link in the first comment below.   #ESMOGI24 ESMO - European Society for Medical Oncology

Medivir team Pia Baumann Malene Jensen Fredrik Oberg on its way to ESMO GI congress in Munich. Exciting days ahead with presentation of new data. In addition, as we have just signed an agreement with a CRO-partner for the upcoming phase 2b study, great timing to engage with liver cancer experts and potential investigators as we have just embarked on the feasibility for the study. More to come, stay tuned! #ESMOGI24 ESMO - European Society for Medical Oncology

Read more on the link below. https://lnkd.in/dvVpuAKH

Medivir participates at Redeye Growth Day 2024 - May 30th. Jens Lindberg, CEO of Medivir, will present the company and the development of fotrox in advanced liver cancer. The event will also be broadcasted live. Event page: https://lnkd.in/dKDM-VfH